# US 2016/0257697 A1 · Thiophene-substituted tetracyclic compounds and methods ofuse thereof for the treatment of viral diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257697 A1
- Document ID: US20160257697A1
- Status: Published application
- Kind: A1
- Application number: 14/761,259
- Filed: 2013-12-31
- Published: 2016-09-08
- Earliest claimed: 2013-01-16
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Ling Tong; Wensheng Yu; Joseph A. Kozlowski; Lei Chen; Oleg Selyutin; Seong Heon Kim; Michael Dwyer; Bin Hu; Bin Zhong; Dahai Wang; Jinglai Hao; Changmao Shen; Zhixin Lei; Weijun Wang
- Web page: https://patentgrep.com/patent/US20160257697A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 38/212: {IFN-alpha}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.

## Claims

### Claim 1

A compound having the formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is:
A′ is:
each occurrence of R1 is independently selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl and halo, or two R1 groups that are attached to the same carbon atom, and the common carbon atom to which they are attached, can combine to form a spirocyclic C3-C7 cycloalkyl group;
each occurrence of R1A is independently selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl and halo, or one R1A group and an R1 group that are attached to same ring, together with the ring carbon atoms to which they are attached, can combine to form a fused C3-C7 cycloalkyl group, or two R1A groups that are attached to the same carbon atom, and the common carbon atom to which they are attached, can combine to form a spirocyclic C3-C7 cycloalkyl group;
each occurrence of R1B is independently H, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl or halo, or an R1B group and an R1A group that are attached to the same ring, together with the carbon atoms to which they are attached, can combine to form a fused C3-C7 cycloalkyl group, or an R1B group and an R1 group that are attached to the same ring, can combine to form a bridging group having the formula —CH2— or —CH2CH2—, or or two R1B groups that are attached to the same carbon atom, and the common carbon atom to which they are attached, can combine to form a spirocyclic C3-C7 cycloalkyl group
R2 is H, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or halo;
R3 is thiophenyl, wherein said thiophenyl group can be optionally substituted on one or more ring carbon atoms with R6;
each occurrence of R4 is independently selected from —C(O)O—(C1-C6 alkyl), —C(O)—C(R7)2NHC(O)O—R8, —C(O)—CH(R7)(R8) and —C(O)—CH(R7)N(R9)2;
R5 represents up to 2 substituents, each independently selected from H, halo, —CN, C1-C6 alkyl, C1-C6 haloalkyl, —(C1-C6 alkylene)m-C3-C7 cycloalkyl, 4 to 6-membered monocyclic heterocycloalkyl, 5 or 6-membered monocyclic heteroaryl, C6-C10 aryl, benzyl and —O—(C1-C6 alkyl), wherein said C3-C7 cycloalkyl group, said 4 to 6-membered monocyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group, said C6-C10 aryl group, or the phenyl moiety of said benzyl group can be optionally substituted with up to 3 groups, which can be the same or different, and are selected from halo, —CN, C1-C6 alkyl, C1-C6 haloalkyl, —O—C1-C6 alkyl, —(C1-C6 alkylene)-O—C1-C6 alkyl and —O—(C1-C6 haloalkyl);
R6 represents up to 2 substituents, each independently selected from halo, —CN, C1-C6 alkyl, —C(O)OH, C1-C6 haloalkyl, —O—(C1-C6 haloalkyl), C2-C6 alkynyl, C1-C6 hydroxyalkyl, —O—C1-C6 alkyl, —(C1-C6 alkylene)-O—(C1-C6 alkyl), —N(R6)2, —C(O)N(R6)2, optionally substituted C6-C10 aryl, —(C1-C6 alkylene), —(C3-C7 cycloalkyl), —O—(C6-C10 aryl), —(C2-C6 alkynyl)-(C3-C7 cycloalkyl), 4 to 7-membered monocyclic heterocycloalkyl, 5 or 6-membered monocyclic heteroaryl, —O-(5 or 6-membered monocyclic heteroaryl), 8 to 10-membered bicyclic heteroaryl and —O-(8 to 10-membered bicyclic heteroaryl), wherein said C6-C10 aryl group, said C3-C7 cycloalkyl group, said 4 to 7-membered monocyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group and said 8 to 10-membered bicyclic heteroaryl group, can be optionally substituted with up to 3 groups, each independently selected from halo, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl and —O—C1-C6 alkyl, and wherein said C6-C10 aryl group, said 5 or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group, can be optionally fused with a 3 to 6 membered cycloalkyl group; and wherein said thiophenyl group can be optionally fused to a benzene ring, a 5 or 6-membered monocyclic heterocycloalkyl group, a 5 or 6-membered monocyclic heteroaryl group or a C5-C6 cycloalkyl group, wherein said 5 or 6-membered monocyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group and said C5-C6 cycloalkyl group can form a spirocycle with a C3-C7 cycloalkyl group or a 4 to 7-membered monocyclic heterocycloalkyl group each occurrence of R7 is independently selected from H, C1-C6 alkyl, C1-C6haloalkyl, —(C1-C6 alkylene)-O—C1-C6 alkyl, phenyl, 4 to 8-membered monocyclic heterocycloalkyl, 6 to 10-membered bicyclic heterocycloalkyl and —(C1-C6 alkylene)m-C3-C7 cycloalkyl, wherein said 4 to 8-membered monocyclic heterocycloalkyl group, said 6 to 10-membered bicyclic heterocycloalkyl group and said C3-C7 cycloalkyl group can be optionally substituted with up to 5 groups, each independently selected from halo, —CN, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, —O—C1-C6 alkyl, —N(R6)2 and —O—(C1-C6 haloalkyl), and wherein said C3-C7 cycloalkyl group can be optionally fused to a 4 to 6-membered monocyclic heterocycloalkyl group, and wherein said 4 to 8-membered monocyclic heterocycloalkyl group and said C3-C7 cycloalkyl group can be substituted on a ring carbon atom with a spirocyclic C3-C6 cycloalkyl group; and wherein said C3-C7 cycloalkyl group can be substituted on a ring carbon atom with a spirocyclic 3 to 6-membered monocyclic heterocycloalkyl group, and wherein two R7 groups, that are attached to a common carbon atom, together with the common carbon atom to which they are attached, join to form a C3-C7 cycloalkyl group;
each occurrence of R8 is independently selected from C1-C6 alkyl, C3-C7 cycloalkyl and C6-C10 aryl;
each occurrence of R9 is independently selected from H, C1-C6 alkyl, C3-C7 cycloalkyl and C6-C10 aryl; and
each occurrence of m is independently 0 or 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R3 is:
which can be optionally substituted as described in claim 1.

### Claim 3 (depends on 1)

The compound of claim 1, wherein each occurrence of R4 is independently —C(O)—C(R7)2NHC(O)O—R8.

### Claim 4 (depends on 1)

The compound of claim 1, wherein A and A′ are each independently selected from:

### Claim 5 (depends on 4)

The compound of claim 4, wherein each occurrence of R4 is independently —C(O)CH(R7)—NHC(O)O—(C1-C6 alkyl) and R7 is C1-C6 alkyl, C1-C6 haloalkyl or 4 to 6-membered monocyclic heterocycloalkyl, wherein said 4 to 6-membered monocyclic heterocycloalkyl group can be optionally substituted with up to five C1-C6 alkyl groups or said 4 to 6-membered monocyclic heterocycloalkyl group can be optionally substituted on a ring carbon atom with a spirocyclic C3-C6 cycloalkyl group.

### Claim 6 (depends on 1)

The compound of claim 1 having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
each R1 is H;
each R1A is H, or an R1A groups and an R1 group that are attached to same ring, together with the ring carbon atoms to which they are attached, can combine to form a fused cyclopropyl group;
R3 is:
wherein R3 can be optionally substituted on one or more ring carbon atoms with a group selected from methyl, ethyl, n-propyl, isopropyl, t-butyl, F, —CHF2, —CH2CF3, —CH2F, —CF3, cyclopropyl, cyclobutyl, cyclopentyl, —CH2-cyclopropyl, methoxy, —O-(halo-substituted phenyl), —OCF3, —C(CH3)2OH, —CH2CH2OCH3, halo-substituted phenyl and —CN;
each occurrence of R5 is independently selected from H, methyl and F;
each occurrence of R7 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and 4 to 6-membered monocyclic heterocycloalkyl, wherein said 4 to 6-membered monocyclic heterocycloalkyl group can be optionally substituted with up to 5 groups, each independently selected from halo, C1-C6 alkyl and C3-C2 cycloalkyl, and wherein said 4 to 6-membered monocyclic heterocycloalkyl group can be optionally substituted on a ring carbon atom with a spirocyclic C3-C6 cycloalkyl group;
each occurrence of R8 is independently C1-C6 alkyl.

### Claim 7 (depends on 6)

The compound of claim 6, having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
R3 is:
Ra is C1-C6 alkyl or C3-C7 cycloalkyl;
R5 is H or F;
each occurrence of R7 is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and tetrahydropyranyl, wherein said tetrahydropyranyl group can be optionally substituted with up to 5 groups, each independently selected from halo, C3-C7 cycloalkyl or C1-C6 alkyl, and wherein said tetrahydropyranyl group can be optionally substituted on a ring carbon atom with a spirocyclic cyclopropyl group.
each occurrence of R8 is methyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein each occurrence of R7 is independently selected from isopropyl, —CF(CH3)2,
and each occurrence of R8 is methyl.

### Claim 9 (depends on 7)

The compound of claim 7, wherein Ra is cyclopropyl, ethyl, cyclopentyl, n-propyl, isopropyl, t-butyl or isobutyl; and R5 is F.

### Claim 10

Any compound numbered 1-853 as described in the above specification or stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11 further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, further comprising a third therapeutic agent selected from the group consisting of HCV protease inhibitors, HCV NS5A inhibitors and HCV NS5B polymerase inhibitors.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method of treating a patient infected with HCV comprising the step of administering an amount of (i) the compound according to claim 1, effective to treat infection by HCV in said patient.

### Claim 16 (depends on 15)

The method according to claim 15, further comprising the step of administering pegylated-interferon alpha and an HCV protease to said patient.

### Claim 17 (depends on 15)

The method according to claim 15, further comprising the step of administering ribavirin to said patient.

### Claim 18 (depends on 15)

The method according to claim 15, further comprising the step of administering from one to three additional therapeutic agents to said patient, wherein the additional therapeutic agents are each independently selected from HCV protease inhibitors, HCV NS5A inhibitors and HCV NS5B polymerase inhibitors.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the one to three additional therapeutic agents comprises MK-5172.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the one to three additional therapeutic agents comprises sofosbuvir.
